Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3399 - Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents


09 Oct 2016


Poster display


Lee Schwartzberg


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


L. Schwartzberg1, K. Jordan2, B.L. Rapoport3, I. Schnadig4, M. Chasen5, S. Arora6, S. Barbour7, D. Powers8, R. Navari9

Author affiliations

  • 1 Hematology & Oncology, The West Clinic, 38138 - Memphis/US
  • 2 Department Of Internal Medicine Iv, Hematology And Oncology, Martin-Luther-University Halle-Wittenberg, 06120 - Halle/DE
  • 3 Medical Oncology, The Medical Oncology Centre of Rosebank, 2196 - Johannesburg/ZA
  • 4 Medical Oncology, Compass Oncology, US Oncology Research, Tualatin/US
  • 5 Department Of Oncology, University of Ottawa, Ottawa/CA
  • 6 Biostatistics, TESARO, Inc., Waltham/US
  • 7 Department Of Oncology Pharmacy, Duke University Medical Center, Durham/US
  • 8 Medical Affairs, TESARO, Inc., Waltham/US
  • 9 Department Of Medicine, Indiana University School of Medicine–South Bend, 46544 - South Bend/US


Abstract 3399


Rolapitant (VARUBI®), a selective, long-acting neurokinin-1 receptor antagonist (RA), effectively prevented chemotherapy-induced nausea and vomiting in phase 3 trials of patients (pts) receiving highly or moderately emetogenic chemotherapy. BCRP transports potentially harmful substances out of cells and is expressed in the liver, kidneys, gastrointestinal tract, and blood-brain barrier. Drugs that are substrates of BCRP have the potential for drug-drug interactions (DDI) when this transporter is inhibited. Rolapitant is an inhibitor of BCRP. However, rolapitant use is not contraindicated in patients administered concomitant BCRP substrate drugs. This post hoc analysis describes the safety of rolapitant in pts receiving chemotherapy agents that are substrates of BCRP.


In 4 randomized, placebo-controlled trials, pts were randomized 1:1 to a single dose of 180 mg oral rolapitant or placebo before chemotherapy. All pts received an oral 5-HT3 RA + dexamethasone (active control). Treatment-emergent AEs (TEAEs) were recorded in all pts receiving BCRP substrate drugs and compared between the rolapitant and control arms.


1637 pts received concomitant BCRP substrate drugs of any kind. Most common BCRP substrate chemotherapy agents in rolapitant and control arms were doxorubicin (22.5% and 23.3%, respectively), fluorouracil (17.3% and 17.7%), and docetaxel (11.4% and 11.4%). Overall, the percentage of pts with ≥1 treatment-related AEs was similar in both arms in pts receiving any concomitant BCRP substrate chemotherapy agent used in the trials. Overall, we saw no apparent increase in TEAEs between pts receiving and not receiving concomitant BCRP substrates.

BCRP substrates* (n rolapitant; n control) Most common TEAEs (%)
Rolapitant Control
Docetaxel (147; 148) Diarrhea (23.8), fatigue (22.4), neutropenia (14.3) Diarrhea (23.0), fatigue (20.3), constipation (17.6)
Doxorubicin (291; 303) Fatigue (19.2), alopecia (13.7), neutropenia (11.0) Fatigue (18.2), headache (16.5), alopecia (14.9)
Fluorouracil (224; 230) Fatigue (11.6), constipation (11.2), asthenia (7.6) Alopecia (10.4), constipation (10.4), fatigue (9.1)
Irinotecan (39; 34) Constipation (10.3), fatigue (10.3), nausea (7.7) Diarrhea (20.6), alopecia (11.8), constipation (8.8)

*Partial list


Rolapitant + 5-HT3 receptor antagonist + dexamethasone was safe and well-tolerated in pts receiving concomitant BCRP substrate chemotherapy agents.

Clinical trial identification

NCT01500226, NCT01499849, NCT01500213

Legal entity responsible for the study





L. Schwartzberg: Consulting or Advisory Role: Eisai, Teva, Amgen, Genentech, Bristol-Myers Squibb; Leadership: Vector Oncology; Speakers' Bureau: Genentech, Novartis, Bristol-Myers Squibb; Stock and Other Ownership Interests: Vector Oncology; Research Funding: Eisai. K. Jordan: Consulting or Advisory Role: Merck, MSD, Helsinn Healthcare, Tesaro. B.L. Rapoport: Consulting or Advisory Role: Tesaro, Merck; Speakers' Bureau: Tesaro, Merck; Travel, Accommodations, Expenses: Tesaro, Merck; Honoraria: Tesaro, Merck. I. Schnadig: Advisory Board: Tesaro. S. Arora, D. Powers: Employment: Tesaro, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings